Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.58 |
| ▸ | RAB9A | P51151 | 9/20 | 0.58 |
| ▸ | NPC1 | O15118 | 8/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | GAA | P10253 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21301181 | 0.83 | KDM4E (0.58) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL4907798 | 0.83 | KDM4E (0.58) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL21699657 | 0.83 | KDM4E (0.58) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL11489855 | 0.83 | KDM4E (0.58) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL21779833 | 0.83 | KDM4E (0.63) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL24182079 | 0.83 | KDM4E (0.63) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL231307 | 0.82 | KDM4E (0.75) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL21362250 | 0.81 | KDM4E (0.59) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL8045063 | 0.81 | KDM4E (0.55) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL12854008 | 0.80 | KDM4E (0.72) | KDM4ERAB9ANPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621916-B1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2016-02-10 | — | — | EP | disclosed |
| CN-103228643-B | As the benzoxazole derivative of histamine h 4 receptor part | BIOPROJET (FR) | 2015-11-25 | — | — | CN | disclosed |
| US-9029357-B2 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJET (FR) | 2015-05-12 | — | — | US | disclosed |
| US-20150004181-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | BIOPROJET SOC CIV (FR) | 2015-01-01 | — | — | US | disclosed |
| US-8802664-B2 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJECT (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20130231329-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | BIOPROJET (FR) | 2013-09-05 | — | — | US | disclosed |
| EP-2621916-A1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET (FR) | 2013-08-07 | — | — | EP | disclosed |
| CN-103228643-A | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJET SOC CIV | 2013-07-31 | — | — | CN | disclosed |
| EP-2447263-A1 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJET (FR) | 2012-05-02 | — | — | EP | disclosed |
| WO-2012041860-A1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET (FR) | 2012-04-05 | — | — | WO | disclosed |
| US-20080299041-A1 | HETEROCYCLIC INDENE DERIVATIVES AND THEIR RADIOISOTOPE LABELED COMPOUNDS FOR IMAGING BETA-AMYLOID DEPOSITION | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004181-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | HRH4, HRH3, HRH2 | KDM4E 1546/4885RAB9A 2931/4885NPC1 2379/4885 |
| US-20130231329-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | HRH4, HRH3, HRH2 | KDM4E 2139/4885RAB9A 2802/4885NPC1 2013/4885 |
| US-20080299041-A1 | HETEROCYCLIC INDENE DERIVATIVES AND THEIR RADIOISOTOPE LABELED COMPOUNDS FOR IMAGING BETA-AMYLOID DEPOSITION | APP, BACE1, PSEN1 | KDM4E 3533/4885RAB9A 2635/4885NPC1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.